Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Study on Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Sponsor: Guangxi Medical University
Listed as NCT04152356, this observational or N/A phase trial focuses on HepatoCellular Carcinoma and remains ongoing. Sponsored by Guangxi Medical University, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting
-
Dec 2019 — Jan 2021 [monthly]
Recruiting
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangxi Medical University
For direct contact, visit the study record on ClinicalTrials.gov .